Abstract
Hepatocellular carcinoma (HCC) is the most frequent primary neoplasm of the liver, and is the fourth most common malignancy worldwide. It is also the third leading cause of cancer-related deaths. Most cases of HCC develop on a pre-existing chronic liver disease, usually due to hepatitis C virus (HCV), hepatitis B virus (HBV), or alcohol. However, between 15% and 50% of HCC develops in the absence of a known etiology of liver disease, and different lines of evidence identify in non-alcoholic fatty liver disease (NAFLD) a possible relevant risk factor for occurrence of HCC. Insulin resistance (IR), steatosis, oxidative stress and imbalances in adipokine/cytokine interplay, the most important factors involved in NAFLD pathogenesis and progression, could also have a determinant role in liver carcinogenesis by promoting cellular growth and DNA damage. Recently, behavioral therapy and various insulin sensitizing agents have been tested in the treatment of NAFLD. A number of studies suggest that these approaches improve IR and reduce steatosis, necroinflammation and fibrosis. A potential role of these therapeutic strategies in the prevention of hepatocarcinogenesis can thus be envisaged.
Keywords: NAFLD, hepatocellular carcinoma, insulin resistance, steatosis, obesity, diabetes
Current Pharmaceutical Design
Title: Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association
Volume: 16 Issue: 6
Author(s): S. Petta and A. Craxi
Affiliation:
Keywords: NAFLD, hepatocellular carcinoma, insulin resistance, steatosis, obesity, diabetes
Abstract: Hepatocellular carcinoma (HCC) is the most frequent primary neoplasm of the liver, and is the fourth most common malignancy worldwide. It is also the third leading cause of cancer-related deaths. Most cases of HCC develop on a pre-existing chronic liver disease, usually due to hepatitis C virus (HCV), hepatitis B virus (HBV), or alcohol. However, between 15% and 50% of HCC develops in the absence of a known etiology of liver disease, and different lines of evidence identify in non-alcoholic fatty liver disease (NAFLD) a possible relevant risk factor for occurrence of HCC. Insulin resistance (IR), steatosis, oxidative stress and imbalances in adipokine/cytokine interplay, the most important factors involved in NAFLD pathogenesis and progression, could also have a determinant role in liver carcinogenesis by promoting cellular growth and DNA damage. Recently, behavioral therapy and various insulin sensitizing agents have been tested in the treatment of NAFLD. A number of studies suggest that these approaches improve IR and reduce steatosis, necroinflammation and fibrosis. A potential role of these therapeutic strategies in the prevention of hepatocarcinogenesis can thus be envisaged.
Export Options
About this article
Cite this article as:
Petta S. and Craxi A., Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association, Current Pharmaceutical Design 2010; 16 (6) . https://dx.doi.org/10.2174/138161210790883787
DOI https://dx.doi.org/10.2174/138161210790883787 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interfering with Protein-Protein Contact: Molecular Interaction Maps and Peptide Modulators
Current Topics in Medicinal Chemistry MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology The Engaged Role of Tumor Microenvironment in Cancer Metabolism: Focusing on Cancer-Associated Fibroblast and Exosome Mediators
Anti-Cancer Agents in Medicinal Chemistry Cdc25A Protein Phosphatase: A Therapeutic Target for Liver Cancer Therapies
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Biological Evaluation of New Quinoline-Based Thiazolyl Hydrazone Derivatives as Potent Antifungal and Anticancer Agents
Letters in Drug Design & Discovery Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer
Current Pharmaceutical Design Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cancer. A Proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD)
Reviews on Recent Clinical Trials ErbB Antagonists Patenting: “Playing Chess with Cancer”
Recent Patents on Biotechnology Honey, Health and Longevity
Current Aging Science Overview of Cantharidin and its Analogues
Current Medicinal Chemistry Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets Meet Our Regional Editor
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis and Structure-Activity Relationship Studies of Novel 4 (1-adamantyl) Phenyl Analogues as HIF-1α Inhibitors
Medicinal Chemistry Intraoperative Targeted Optical Imaging: A Guide towards Tumor-Free Margins in Cancer Surgery
Current Pharmaceutical Biotechnology Multiple Hormonal Dysregulation as Determinant of Low Physical Performance and Mobility in Older Persons
Current Pharmaceutical Design Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery